Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
538.5 USD | +6.14% | +3.27% | +14.19% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+14.19% | 125B | A- | ||
-5.91% | 456B | B- | ||
+15.08% | 97.9B | B- | ||
-21.78% | 43.15B | A- | ||
-3.53% | 38.2B | B- | ||
-12.93% | 18.43B | B- | ||
-27.51% | 2.57B | C+ | ||
-8.59% | 1.5B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ELV Stock
- Ratings Elevance Health, Inc.